CRNX

NEUTRALM&A

Crinetics Pharmaceuticals, Inc.

2026-08-31

Price

$84.95

+0.13%

This is the 2026-08-31 snapshot — the signals and analysis for CRNX as of this single trading day.

View full CRNX research hub →

Score14.5Priority

Signals7/8 DNA1/13 Act · 2/4 Risk

SentimentNEUTRALScore: 10

Volume3.4xvs 20d avg

Analysis

CRNX is trading directly on the mechanics of its imminent $85.00 all-cash acquisition by Vertex Pharmaceuticals, completely decoupling from broader equity market fluctuations. The technical signals of SURGE and STEADY_CLIMB, combined with a massive 3.4x volume spike, reflect final merger arbitrage positioning as the stock pins at $84.95. Furthermore, the current RISK_ON macro regime and ultra-low credit spreads (0.79% OAS) have provided a frictionless environment for corporate M&A, giving the market absolute conviction that the deal will close without financing hiccups.

Fired Signals

SURGEALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSMARKET LEADERPERFECT STACKQUIET ACCUMULATIONWEAK FINISHCHURNING

Key Takeaways

Actionable Thesis: CRNX is a pure merger arbitrage completion play pinned at $84.95, offering nominal pennies to the $85.00 deal price before tonight's scheduled trading halt.
Key Risk: A highly improbable 11th-hour regulatory or legal injunction that delays the September 1st closing.
What to Watch: The scheduled after-hours trading halt at 7:50 PM ET today and the official deal closure prior to the market open tomorrow.

← Back to 2026-08-31 View Full CRNX History →Yahoo Finance &nearr;